[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: MRG-001: Plerexifor (AMD3100; 24mg/mL) and tacrolimus (FK506; 0.5mg/mL).Subjects enrolled will receive study drug 0.0067 mL/kg of subject body weight. Study drug will be administered through the skin of the abdominal wall SC every other day (QAD) for 13 days.Control Intervention1: Placebo: 0.9% Saline. Subjects enrolled will receive Placebo 0.0067 mL/kg of subject body weight. Placebo will be administered through the skin of the abdominal wall SC every other day (QAD) for 13 days.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: MRG-001: Plerexifor (AMD3100; 24mg/mL) and tacrolimus (FK506; 0.5mg/mL).Subjects enrolled will receive study drug 0.0067 mL/kg of subject body weight. Study drug will be administered through the skin of the abdominal wall SC every other day (QAD) for 13 days.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Placebo: 0.9% Saline. Subjects enrolled will receive Placebo 0.0067 mL/kg of subject body weight. Placebo will be administered through the skin of the abdominal wall SC every other day (QAD) for 13 days.", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2368, "treatment_name": "Plerixafor+tacrolimus", "treatment_type": "Other targeted therapies+immunosuppressants", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]